HAYWARD, CA -- (MARKET WIRE) -- November 20, 2006 -- Aradigm Corporation (PINKSHEETS: ARDM) today announced that the results of the Phase 2a clinical trial program of inhaled hydroxychloroquine (HCQ) as treatment for patients with moderate-persistent asthma, conducted on behalf of and funded by APT Pharmaceuticals (“APT”), did not meet the pre-specified clinical efficacy endpoints. No serious adverse events were reported either related to the drug or Aradigm’s AERx delivery system.
